查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1375851

人类免疫力缺乏病毒治疗药物市场规模、份额、趋势分析报告：按药物类型、药物类别、地区和细分市场预测，2023-2030 年

Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Drug Class (Entry & Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 75 Pages | 商品交期: 2-10个工作天内

价格

人类免疫力缺乏病毒治疗药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，2023年至2030年，全球人类免疫力缺乏病毒（HIV）-1治疗药物市场规模将以1.5%的年复合成长率增长，到2030年将达到113.4亿美元。预计达到美元。

爱滋病毒仍然是全球最具挑战性的公共卫生议题之一。

推动市场成长的关键因素包括爱滋病毒感染率上升，特别是在青少年中，由于无保护性行为、接触被感染体液和组织污染的针头和注射器，以及缺乏对感染危险因素的认识，据说这种情况正在增加。据英国的爱滋病毒/爱滋病慈善机构 AVERT 称，2015 年估计有超过 3500 万人罹患了爱滋病毒。

爱滋病毒对开发中国家和低度开发国家（主要是亚洲和非洲）的人们有重大影响。由于这种感染疾病目前无法治愈，抗逆转录病毒治疗的首要目标是使用抗逆转录病毒病毒药物治疗患者的病毒，抗逆转录病毒药物根据其作用机制分为六种不同的药物类别，即抑制复製。

联合治疗使用至少两到三种药物类别的药物，因为每一类药物针对爱滋病毒生命週期的不同步骤。药物组合的选择是基于患者的病历、抗逆转录病毒病毒药物副作用的倾向以及与其他疾病的合併感染。

人类免疫力缺乏病毒治疗药物市场报告亮点

  • 整合酶抑制剂领域是成长最快的一类抗逆转录病毒药物，吉利德科学公司和默克公司等主要公司预计将推出更多整合酶抑制剂。
  • 2022年，北美市场占有率最大，超过51.5%。诊断设施的便利性是支持该地区市场扩张的关键因素之一。
  • 亚太地区是成长最快的地区，由于拥有发达的医疗基础设施和适当的政府促进成长措施，预计在预测期内将保持其地位。
  • 就市场占有率和药物组合而言，吉利德科学公司 (Gilead Sciences) 是 HIV-1 治疗领域的领导者，2015 年 ViiV Healthcare 紧随其后。此外，预计其他较小的参与者将在未来几年内透过管道药物进入该领域。
  • 该产业的其他重要参与者包括艾伯维公司、百时美施贵宝公司和默克公司。

目录

第1章调查方法和范围

第2章执行摘要

第3章人类免疫力缺乏病毒治疗药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 人类免疫力缺乏病毒疗法：市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章人类免疫力缺乏病毒治疗药物市场：药物类型估算及趋势分析

  • 人类免疫力缺乏病毒治疗市场：重点
  • 人类免疫力缺乏病毒治疗市场：2022 年和 2030 年药物类型趋势和市场占有率分析
  • 品牌药品
  • 仿製药

第5章人类免疫力缺乏病毒治疗药物市场：药物类别估计和趋势分析

  • 人类免疫力缺乏病毒治疗市场：重点
  • 人类免疫力缺乏病毒治疗市场：2022 年和 2030 年药物类别趋势和市场占有率分析
  • 核苷类似物逆转录酶抑制剂 (NRTI)
  • 非核苷类逆转录酶抑制剂（NNRTI）
  • 进入抑制剂和融合抑制剂
  • 蛋白酶抑制剂 (PI)
  • 整合酶抑制剂
  • 共受体拮抗剂

第6章人类免疫力缺乏病毒治疗药物市场：按地区估计和趋势分析

  • 区域展望
  • 按地区分類的人类免疫力缺乏病毒治疗市场：要点
  • 北美洲
    • 2018-2030 年北美市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030 年欧洲市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 2018-2030 年亚太市场估计与预测
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市场估计与预测
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 2018 年至 2030 年 MEA 市场估计与预测
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • Genentech, Inc.
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • ViiV Healthcare
Product Code: GVR-1-68038-210-5

Human Immunodeficiency Virus Therapeutics Market Growth & Trends:

The global Human Immunodeficiency Virus (HIV)-1 therapeutics market size is expected to reach USD 11.34 billion by 2030, expanding at a CAGR of 1.5% from 2023 to 2030, according to a new report by Grand View Research, Inc.. HIV continues to be one of the most challenging public health issues worldwide.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients' medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.

Human Immunodeficiency Virus Therapeutics Market Report Highlights:

  • Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.
  • North America held the largest market share in 2022 with a share of over 51.5%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.
  • Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth
  • Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed byViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.
  • Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug type
    • 1.1.2. Drug class
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug type outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Human Immunodeficiency Virus Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Human Immunodeficiency Virus Therapeutics: Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Human Immunodeficiency Virus Therapeutics Market: Drug Type Estimates & Trend Analysis

  • 4.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
  • 4.2. Human Immunodeficiency Virus Therapeutics Market: Drug Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Branded Drugs
    • 4.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Generic Drugs
    • 4.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Human Immunodeficiency Virus Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 5.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
  • 5.2. Human Immunodeficiency Virus Therapeutics Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • 5.3.1. Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 5.4.1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Entry and Fusion Inhibitors
    • 5.5.1. Entry and fusion inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Protease Inhibitors (PIs)
    • 5.6.1. Protease inhibitors (PIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Integrase Inhibitors
    • 5.7.1. Integrase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Coreceptor Antagonists
    • 5.8.1. Coreceptor antagonists market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Human Immunodeficiency Virus Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Human Immunodeficiency Virus Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. UK
      • 6.4.2.1. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. France
      • 6.4.4.1. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.9. Denmark
      • 6.4.9.1. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. China
      • 6.5.3.1. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. India
      • 6.5.4.1. India market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.7. South Korea
      • 6.5.7.1. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Mexico
      • 6.6.3.1. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.4. Argentina
      • 6.6.4.1. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
    • 6.7.3. South Africa
      • 6.7.3.1. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. AbbVie Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Boehringer Ingelheim International GmbH
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Bristol-Myers Squibb Company
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Cipla Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Genentech, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Gilead Sciences, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Merck & Co., Inc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. ViiV Healthcare
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 3 North America human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 6 U.S. human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Canada human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 8 Canada human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 Europe human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Europe human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Europe human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Germany human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 UK human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 UK human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 France human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 France human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Italy human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 19 Italy human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Spain human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 21 Spain human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Sweden human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 Sweden human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Norway human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 25 Norway human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Denmark human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Denmark human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 China human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Japan human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 Japan human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 India human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 36 India human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Australia human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Australia human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Thailand human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 40 Thailand human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 41 South Korea human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 South Korea human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Latin America human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 44 Latin America human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 Latin America human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 47 Brazil human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Mexico human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 49 Mexico human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Argentina human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 Argentina human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 56 South Africa human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 UAE human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 UAE human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 61 Kuwait human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Human immunodeficiency virus therapeutics: Market outlook
  • Fig. 9 Human immunodeficiency virus therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Human immunodeficiency virus therapeutics market driver impact
  • Fig. 15 Human immunodeficiency virus therapeutics market restraint impact
  • Fig. 16 Human immunodeficiency virus therapeutics market strategic initiatives analysis
  • Fig. 17 Human immunodeficiency virus therapeutics market: Drug type movement analysis
  • Fig. 18 Human immunodeficiency virus therapeutics market: Drug type outlook and key takeaways
  • Fig. 19 Branded drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Human immunodeficiency virus therapeutics market: Drug class movement analysis
  • Fig. 22 Human immunodeficiency virus therapeutics market: Drug class outlook and key takeaways
  • Fig. 23 Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Entry and fusion inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Protease inhibitors (PIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Integrase inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Coreceptor antagonists market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global human immunodeficiency virus therapeutics market: Regional movement analysis
  • Fig. 30 Global human immunodeficiency virus therapeutics market: regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)